Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Autoimmune Disorders

Autoimmune Disorders

Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...

Protein Complex Assembly

Protein Complex Assembly

Proteins can form homomeric complexes with another unit of the same protein or heteromeric complexes with different types. Most protein complexes self-assemble spontaneously via ordered pathways, while some proteins need assembly factors that guide their proper assembly. Despite the crowded intracellular environment, proteins usually interact with their correct partners and form functional complexes.
Many viruses self-assemble into a fully functional unit using the infected host cell to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Exploring patients' experiences with wAIHA and the content validity of the FACIT-fatigue: a qualitative interview study.

Orphanet journal of rare diseases·2025

Same author

Outpatient subcutaneous alemtuzumab is feasible and safe for aplastic anemia and is associated with high response rates.

Blood advances·2024

Same author

The Importance of Controlling Terminal Complement Activity and Intravascular Hemolysis in Paroxysmal Nocturnal Hemoglobinuria (PNH).

American journal of hematology·2024

Same author

Sustained improvements in patient-reported outcomes after long-term sutimlimab in patients with cold agglutinin disease: results from the CADENZA study open-label extension.

EClinicalMedicine·2024

Same author

Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease.

Blood advances·2024

Same author

Real-world use of thrombopoietin receptor agonists for the management of immune thrombocytopenia in adult patients in the United Kingdom: Results from the TRAIT study.

British journal of haematology·2024

Same journal

Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 2023;2023(1):382-385.

Hematology. American Society of Hematology. Education Program·2025

Same journal

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.

Hematology. American Society of Hematology. Education Program·2025

Same journal

Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.

Hematology. American Society of Hematology. Education Program·2025

Same journal

Anticoagulants in hematologic malignancies: what is the data?

Hematology. American Society of Hematology. Education Program·2025

Same journal

Diagnosis and management of cold agglutinin disease.

Hematology. American Society of Hematology. Education Program·2025

Same journal

What to know about rare B-cell malignancies in 2025.

Hematology. American Society of Hematology. Education Program·2025

See all related articles

Search research articles

Related Experiment Video

Updated: Feb 1, 2026

Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management

Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management

Published on: January 19, 2024

Autoimmune hemolytic anemia.

Anita Hill¹, Quentin A Hill¹

¹Department of Haematology, Leeds Teaching Hospitals, Leeds, United Kingdom.

Hematology. American Society of Hematology. Education Program

|December 4, 2018

Summary

This summary is machine-generated.

Diagnosing autoimmune hemolytic anemia (AIHA) involves identifying hemolysis and its immune cause. Current treatments include rituximab and complement inhibitors, with new therapies like sutimlimab in development.

More Related Videos

A Rapid, Simple, and Standardized Homogenization Method to Prepare Antigen/Adjuvant Emulsions for Inducing Experimental Autoimmune Encephalomyelitis

A Rapid, Simple, and Standardized Homogenization Method to Prepare Antigen/Adjuvant Emulsions for Inducing Experimental Autoimmune Encephalomyelitis

Published on: December 9, 2022

Identification of Hemolytic and Phospholipase Activity in Crude Extracts from Sea Anemones by Straightforward Bioassays

Identification of Hemolytic and Phospholipase Activity in Crude Extracts from Sea Anemones by Straightforward Bioassays

Published on: March 29, 2022

Related Experiment Videos

Last Updated: Feb 1, 2026

Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management

Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management

Published on: January 19, 2024

A Rapid, Simple, and Standardized Homogenization Method to Prepare Antigen/Adjuvant Emulsions for Inducing Experimental Autoimmune Encephalomyelitis

A Rapid, Simple, and Standardized Homogenization Method to Prepare Antigen/Adjuvant Emulsions for Inducing Experimental Autoimmune Encephalomyelitis

Published on: December 9, 2022

Identification of Hemolytic and Phospholipase Activity in Crude Extracts from Sea Anemones by Straightforward Bioassays

Identification of Hemolytic and Phospholipase Activity in Crude Extracts from Sea Anemones by Straightforward Bioassays

Published on: March 29, 2022

Area of Science:

Hematology
Immunology
Clinical Medicine

Background:

Autoimmune hemolytic anemia (AIHA) is characterized by hemolysis due to autoantibodies.
Diagnosis requires identifying hemolysis and confirming immune mediation via direct anti-globulin test.
Exclusion of other causes and identification of AIHA type are crucial steps.

Purpose of the Study:

To outline the diagnostic approach to AIHA.
To review current and emerging therapeutic strategies for AIHA.
To discuss future treatment prospects for AIHA.

Main Methods:

Stepwise diagnostic approach for AIHA.
Review of current treatment guidelines and clinical trial data.
Exploration of novel therapeutic agents.

Main Results:

Rituximab is a preferred treatment for warm AIHA and cold agglutinin disease (CAD).
Complement inhibitors offer utility in managing acute severe hemolysis in AIHA.
Sutimlimab (BIVV009), a C1s inhibitor, shows promise for CAD in phase 3 studies.

Conclusions:

A structured diagnostic process is essential for AIHA.
Current therapies like rituximab and complement inhibitors are effective.
Emerging treatments, including C1s inhibitors, hold significant potential for AIHA management.